Psychosocial Functioning in Patients with Schizophrenia Treated with
Aripiprazole – an Office-based Real-world Setting. Results from the German Post-marketing Surveillance Study
Pharmacopsychiatry, 0Bergmann F et al. - The results indicate that aripiprazole may be an efficacious and safe treatment option for pre-treated patients with
schizophrenia also in a naturalistic psychiatrist/neurologist practice setting with effects on health and psychosocial functioning and a comparably low dropout rate.
- Efficacy was rated by using standard CGI, SF-12® and SIWM-PsySo® instruments for severity of disease, physical and mental health outcomes and psychosocial state, respectively.
- Safety was evaluated according to the reports of adverse events.
- Mean total daily dose of aripiprazole increased from 15.4 mg at the visit after 1 month to 17.6 mg at the visits after 6 to 12 months, the most frequently administered maintenance dose being 15 mg.
- Within the observation period significant improvements of CGI, SF-12® and SIWM-PsySo® scores over time versus baseline values were observed (p<0.001) when starting with or switching to aripiprazole.
- Physicians observed improvements in 80.7% of the patients at endpoint; in 62% of the patients the disease state was considered “much” or “very much” improved.
- Aripiprazole was overall well tolerated; 19.9% of patients discontinued treatment after 12 months.
- Adverse effects in general were moderate to mild and corresponded to the known tolerability profile of aripiprazole.
- Psychotic side effects reported were probably due to a recurrence of the underlying schizophrenic disorde
No comments:
Post a Comment